BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 851,400 shares of common stock to 25 new employees under the Company’s 2024 Inducement Plan.

华盛顿州博瑟尔市。--（商业新闻短讯）--Immunome，Inc.（以下简称“公司”）（纳斯达克：IMNM）是一家专注于开发一流和一流靶向癌症治疗的生物技术公司，今天宣布，2024年10月3日，公司董事会薪酬委员会（“薪酬委员会”）根据公司2024年激励计划，授予25名新员工由非法定股票期权组成的激励奖励，以购买851400股普通股。

The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4)..

薪酬委员会根据纳斯达克上市规则5635（c）（4）批准股票期权作为此类员工就业的诱因材料。。

Each stock option has an exercise price per share equal to $13.43 per share, the Company’s closing sales price on October 3, 2024, except for certain options to purchase 250,000 shares that have an exercise price equal to the Company’s closing sales price on the date the grantee’s employment commences and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates.

每个股票期权的每股行权价格等于每股13.43美元，即2024年10月3日公司的收盘销售价格，但购买250000股的某些期权除外，这些期权的行权价格等于受让人开始受雇之日公司的收盘销售价格，并将在四年内授予，25%的标的股份在适用的授予开始日期的一周年纪念日授予，标的股份的余额在36个月内每月授予，但新员工在适用的授予日期与公司保持持续的服务关系。

The stock options are subject to the terms and conditions of the Company’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant..

股票期权受公司2024年激励计划的条款和条件以及涉及授予的适用股票期权协议的条款和条件的约束。。

About Immunome

关于免疫组

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs).

Immunome是一家针对临床阶段的肿瘤公司，致力于开发一流和一流的靶向治疗，旨在改善癌症患者的预后。我们正在推进创新的治疗组合，利用以前在尖端靶向癌症治疗（包括抗体-药物偶联物（ADC））的设计，开发和商业化中发挥关键作用的领导力。

In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025.

除了发现阶段的ADC组合外，我们的管道还包括AL102（一种目前正在进行治疗类胶质瘤的3期临床试验的γ分泌酶抑制剂），以及IM-1021（一种ROR1 ADC）和IM-3050（一种针对FAP的放射性配体），这两种药物都是IND的主题，预计将在2025年第一季度提交。

For more information, visit www.immunome.com..

。。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings; and other statements regarding forecasts for the future.

本新闻稿中并非纯粹历史性的声明是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。；以及其他关于未来预测的声明。

These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024, and in Immunome’s other filings with the SEC.

这些前瞻性陈述基于Immunome目前的预期，并涉及可能永远不会实现或可能被证明不正确的假设；因此，由于多种因素，实际结果可能与报表中明示或暗示的结果存在重大差异，包括但不限于Immunome于2024年8月12日向SEC提交的截至2024年6月30日的季度报表10-Q中所述的风险和不确定性，以及Immunome向SEC提交的其他文件中所述的风险和不确定性。

Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release..

除非法律要求，Immunome不承担任何义务，也不打算更新本新闻稿中包含的任何前瞻性声明。。